Viking Therapeuti…
USUSDViking Therapeutics Inc (MI:1VKTX) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 4. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- vikingtherapeutics.com
- Investor Relations
- ir.vikingtherapeutics.com/ir-contacts
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- SAN DIEGO, United States
- CEO
- Brian Lian
- Mitarbeiter
- 65
- Gegründet
- 2012
- Ausstehende Aktien
- Streubesitz
- 113.73 Mio.
- Marktkapitalisierung
- 4.11 Mrd. USD
- Insider
- 2.87%
- Institutionelle Anleger
- 61.16%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsform
- XTIQ
- ISIN
- US92686J1060
- LEI
- 529900IVC72YPFA25M37
- P/E
- Verlust
- FCF
- −418 Mio. USD
- Schulden
- ?
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
- NAV
Beschreibung
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| FMR, LLC | 5.43% | 6.34 Mio. | 2026-06-30 |
| Blackrock Inc. | 5.31% | 6.19 Mio. | 2026-06-30 |
| State Street Corporation | 4.81% | 5.61 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 4.33% | 5.05 Mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 3.84% | 4.48 Mio. | 2026-06-30 |
| Two Sigma Investments, L… | 3.38% | 3.94 Mio. | 2026-06-30 |
| SPDR SERIES TRUST-State… | 3.24% | 3.78 Mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3% | 3.5 Mio. | 2026-06-30 |
| Morgan Stanley | 2.99% | 3.49 Mio. | 2026-06-30 |
| LIAN BRIAN (Chief Execut… | ≈2.2% | 2.57 Mio. | 2026-07-29 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 2.53 Mio. | 2026-06-30 |
| Ameriprise Financial, In… | 1.85% | 2.16 Mio. | 2026-06-30 |
| Geode Capital Management… | 1.8% | 2.1 Mio. | 2026-06-30 |
| American Century Compani… | 1.56% | 1.82 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.25% | 1.46 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.14% | 1.33 Mio. | 2026-06-30 |
| American Century Mutual… | 1.14% | 1.33 Mio. | 2026-06-30 |
| Fidelity Advisor Series… | 0.91% | 1.06 Mio. | 2026-07-31 |
| Fidelity Concord Street… | 0.49% | 575 573 | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.48% | 555 687 | 2026-05-31 |
| Fidelity Select Portfoli… | 0.46% | 540 000 | 2026-07-31 |
| MANCINI MARIANNA (Chief… | ≈0.36% | 422 760 | 2026-07-29 |
| ZANTE GREGORY S (Chief F… | ≈0.18% | 212 204 | 2026-07-29 |
| FOEHR MATTHEW W (Directo… | ≈0.12% | 135 186 | 2026-01-02 |
| MACARTNEY LAWSON (Direct… | ≈0.04% | 51 115 | 2026-01-02 |
| ROWLAND CHARLES A JR (Di… | ≈0.03% | 33 150 | 2026-01-02 |
| SINGLETON J MATTHEW (Dir… | ≈0.01% | 12 650 | 2026-01-02 |
| KELLY-GEMMELL DOROTHY EL… | ≈0.01% | 6 333 | 2026-07-31 |
| AUBUCHON NEIL WILLIAM (O… | ≈0% | 4 475 | 2026-03-10 |
| ROUAN SARAH KATHRYN (Dir… | ≈0% | 4 390 | 2026-01-02 |
Mit Google Anmelden